Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Starting soon Observational

Evaluation of the Diagnostic Capacity of a Smart Mattress Versus Conventional Polysomnography

NCT07432919 · tracked via the Priya Life Science Spain tracker
Sponsor
Hospital San Pedro de Logroño
Phase
Observational
Started
2026-11-17
Last updated
2026-03-03

Condition(s) studied

Obstructive Sleep Apnea (OSA)

Investigational drug(s) / intervention(s)

Integrated polysomnographic assessment with smart mattress.

Integrated polysomnographic assessment with smart mattress.: During a single night of recording, the participant will sleep on a smart mattress equipped with sensors for the continuous monitoring of sleep parameters. The data obtained will subsequently be compared and validated against polysomnography (PSG) recordings, considered the gold-standard reference for the objective evaluation of sleep architecture and quality, as well as respiratory events.

Study summary

This project aims to develop and evaluate an innovative, non-invasive diagnostic system based on a smart mattress for detecting obstructive sleep apnea (OSA), as well as assessing overall sleep quality and identifying periodic limb movements. The main goal is to improve the accuracy of sleep apnea diagnosis while providing a less invasive solution suitable for home use, ultimately enhancing patients' quality of life.

A descriptive, observational, prospective study will be conducted to analyze data obtained from diagnostic polysomnographies performed at the Sleep Unit of San Pedro Hospital between November 17, 2026, and March 1, 2028. Patients will use the smart mattress, and its measurements will be compared with polysomnography results. This comparison will allow for the optimization of the mattress's artificial intelligence, training it to accurately recognize respiratory patterns and sleep-related events, including positional apneas and periodic limb movements.

Key technical objectives include:

Determining the sensitivity, specificity, and predictive values of the mattress in detecting apneas, hypopneas, and limb movements compared to polysomnography.

Evaluating the agreement between the mattress and polysomnography for sleep variables such as total sleep time, sleep efficiency, sleep stages, micro-arousals, and patient position.

Assessing whether measurement accuracy varies by sleeping position or age group (adults vs. children).

Measuring subjective sleep quality using the Groningen Sleep Quality Scale (GSQS-8).

Performing a descriptive analysis of patient demographics.

Hypotheses:

The smart mattress will detect obstructive sleep apnea, sleep quality, and periodic limb movements with accuracy comparable to polysomnography.

The system will provide a reliable, non-invasive, home-friendly diagnostic method.

Measurements of the apnea-hypopnea index (AHI) and limb movements will show high sensitivity, specificity, and predictive values, both overall and according to OSA severity.

There will be good agreement between mattress measurements and polysomnography for most sleep variables.

Accuracy may vary depending on the patient's sleeping position.

Measurements will correlate well across adults and pediatric patients.

Subjective sleep quality scores (GSQS-8) will be consistent with objective mattress data.

This project seeks to develop a more accurate, accessible, and non-invasive diagnostic system for OSA, combining advanced technology with ease of home use. By training the mattress's AI to recognize sleep patterns and events, it aims to optimize the detection of positional apneas, providing patients with better monitoring, early intervention, and improved quality of life.

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * Polysomnographies performed at San Pedro Hospital between November 17, 2026, and March 1, 2028. * Polysomnographies of patients under 16 years of age and polysomnographies performed at San Pedro Hospital on patients over 16 years of age (as separate study groups). Exclusion Criteria: * Poor technical quality of the polysomnography. * Patients with \>50% central apneas or presence of Cheyne-Stokes respiration (CSResp). * Lack of polysomnography analysis and/or mattress data.

Primary outcome measure(s)

  • Diagnostic accuracy of the smart mattress for detecting sleep apnea. — Night of simultaneous PSG and mattress recording (one night per participant).
    Measured by: Sensitivity Specificity Predictive values (PPV/NPV) Compared with polysomnography (PSG).

Trial sites (2)

FacilityCityRegionStatus
Center for Biomedical Research of La Rioja Logroño La Rioja
San Pedro University Hospital Logroño La Rioja

More Hospital San Pedro de Logroño trials in Spain

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07432919 on ClinicalTrials.gov ↗ ← All trials in Spain